98 related articles for article (PubMed ID: 8867484)
41. Evaluation of the metabolic compensation after treadmill test in patients with peripheral occlusive arterial disease.
Duprez D; De Buyzere M; Van Wassenhove A; Clement D
Angiology; 1992 Feb; 43(2):126-33. PubMed ID: 1536473
[TBL] [Abstract][Full Text] [Related]
42. Effects of prolonged L-arginine administration on blood pressure in patients with essential hypertension (EH).
Malczewska-Malec M; Goldsztajn P; Kawecka-Jaszcz K; Czarnecka D; Siedlecki A; Siemienska T; Dembinska-Kiec A
Agents Actions Suppl; 1995; 45():157-62. PubMed ID: 7717174
[TBL] [Abstract][Full Text] [Related]
43. [Aggregation inhibitors or anticoagulants in the prevention of peripheral arterial occlusive diseases].
Loew D; Hess H
Med Welt; 1982 Oct; 33(43):1511-5. PubMed ID: 6759847
[No Abstract] [Full Text] [Related]
44. Argatroban increases nitric oxide levels in patients with peripheral arterial obstructive disease: placebo-controlled study.
Ueki Y; Matsumoto K; Kizaki Y; Yoshida K; Matsunaga Y; Yano M; Miyake S; Tominaga Y; Eguchi K
J Thromb Thrombolysis; 1999 Aug; 8(2):131-7. PubMed ID: 10436143
[TBL] [Abstract][Full Text] [Related]
45. [Drug therapy of arterial diseases. A study with Trental 400].
Tannenberg G
Fortschr Med; 1980 Dec; 98(45):1795-8. PubMed ID: 7461576
[TBL] [Abstract][Full Text] [Related]
46. [Intravenous infusions in the treatment of arterial occlusive diseases from the surgical point of view].
Hugeneck J
Wien Med Wochenschr; 1976 Sep; 126(38):542-4. PubMed ID: 788353
[No Abstract] [Full Text] [Related]
47. Increased endogenous nitric oxide production induced by physical exercise in peripheral arterial occlusive disease patients.
Arosio E; Cuzzolin L; De Marchi S; Minuz P; Degan M; Crivellente F; Zannoni M; Benoni G
Life Sci; 1999; 65(26):2815-22. PubMed ID: 10622270
[TBL] [Abstract][Full Text] [Related]
48. [Drug therapy of arteriosclerotic circulatory disorders].
Nobbe F
Z Allgemeinmed; 1974 Jul; 50(21):957-64. PubMed ID: 4152664
[No Abstract] [Full Text] [Related]
49. Reaction of transcutaneous PO2 and laser Doppler flow signal on intraarterial infusion of PGE1 and nucleotide phosphates in patients with peripheral arterial occlusive disease.
Caspary L; Creutzig A; Alexander K
Vasa Suppl; 1987; 17():17-22. PubMed ID: 3470960
[No Abstract] [Full Text] [Related]
50. Transcutaneous PO2 response to transient arterial occlusion in peripheral vascular disease detected by heating power oximeter.
Frau G
Angiology; 2001 Dec; 52(12):851-7. PubMed ID: 11775627
[TBL] [Abstract][Full Text] [Related]
51. Treatment of peripheral vascular disease with misoprostol (Cytotec): a pilot study.
Goszcz A; Grodzinska L; Kostka-Trabka E; Bieron K; Slawinski M; Jachym R; Ochmanski W
Methods Find Exp Clin Pharmacol; 1998 Jun; 20(5):439-45. PubMed ID: 9701783
[TBL] [Abstract][Full Text] [Related]
52. [Therapeutic activity of anti-platelet aggregation agents in arterial diseases].
Delboy C; Jouve R; Escande M; Juhan I; Bouvenot G
Sem Hop Ther; 1977 Nov; 53(9):431-40. PubMed ID: 341318
[No Abstract] [Full Text] [Related]
53. [Intra-arterial administration of penicillin and vasodilating agents in occlusive diseases of the peripheral arteries].
Hubl S; Wesolowski J
Pol Tyg Lek; 1973 Jul; 28(30):1150-1. PubMed ID: 4732712
[No Abstract] [Full Text] [Related]
54. Beneficial effect of PGI2 on circulating endothelial cells.
Sinzinger H; Rauscha F; Fitscha P; Kaliman J
Basic Res Cardiol; 1988; 83(6):597-601. PubMed ID: 3066339
[TBL] [Abstract][Full Text] [Related]
55. Effects of garlic coated tablets in peripheral arterial occlusive disease.
Kiesewetter H; Jung F; Jung EM; Blume J; Mrowietz C; Birk A; Koscielny J; Wenzel E
Clin Investig; 1993 May; 71(5):383-6. PubMed ID: 8508009
[TBL] [Abstract][Full Text] [Related]
56. [Therapeutic fibrinolysis and arterial occlusive disease].
Lasch HG; Schöndorf TH
Verh Dtsch Ges Inn Med; 1981; 87():314-23. PubMed ID: 7331461
[No Abstract] [Full Text] [Related]
57. [A treatment possibility of arterial occlusive diseases with calcitonin. Retrospect of 16 years experience in over 200 patients between 20 and 99 years of age].
Staehelin A; Weidmann M; Staehelin E; Horat R
Vasa Suppl; 1988; 26():194-6. PubMed ID: 3201373
[No Abstract] [Full Text] [Related]
58. [Possibilities and limitations in the diagnosis and therapy of peripheral arterial circulatory disorders in ambulatory practice].
Kamp O
Z Arztl Fortbild (Jena); 1977 Feb; 71(3):126-31. PubMed ID: 848061
[No Abstract] [Full Text] [Related]
59. [Hypocobaltemia in chronic obstructive arteriopathy. Physiopathologic and therapeutic importance].
Zotti GC; Frongillo P; Micheletti G; De Franciscis G; Navarra S; Testa S; Sacco M; Bracale GC
Minerva Chir; 1993 Feb; 48(3-4):147-52. PubMed ID: 8479650
[TBL] [Abstract][Full Text] [Related]
60. [Therapeutic value of a new anti-ischemic and vaso-regulating drug: Cètièdil].
Linquette M; Fossati P; Luez G
Lille Med; 1973 Dec; 18(10 Suppl 5):suppl 5:1303-12. PubMed ID: 4802992
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
